ClinicalTrials.gg
RecruitingNCT06318260DobATTRUpdated Jun 1, 2026

Haemodynamic Effects of Dobutamine in Patients With Wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt)

A Phase 1/2 interventional study of Dobutrex in ATTR Amyloidosis Wild Type, sponsored by Steen Hvitfeldt Poulsen. Recruiting at 1 site in Denmark. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-06-01.

Sponsored by Steen Hvitfeldt Poulsen · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark — 6 open to participants now, 7 under way, 2 of them phase 3. Amyloid Neuropathies, Familial · Denmark.

Started
2024
with 1 other
Phase 1/2
Only one
of the 11
Registered
8th of 11
by date
Lead sponsor
4 of 11
Steen Hvitfeldt Poulsen

Among the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, this one is one of 2 that started in 2024, is the only one in phase 1/2, and was the 8th registered.

Amyloid Neuropathies, Familial

188 studies on the registry are indexed under Amyloid Neuropathies, Familial; 94 are open to participants now.

Browse Amyloid Neuropathies, Familial studies →

Open to participants now

6 of the 11 studies in Amyloid Neuropathies, Familial with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 69 Amyloid Neuropathies, Familial studies recruiting now, 53 (77%) set no upper age limit and 1 (1%) stops at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyloid Neuropathies, Familial with a site in Denmark, or all of them as a file.
02

Study summary

The goal of this clinical trial is to test the effects of the inotropic drug named dobutamine, in patients with wild-type Transthyretin Amyloid Cardiomyopathy (ATTRwt). The main questions it aims to answer are:

  • What are the effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt.
  • Safety of dobutamine infusion in this patient population.

Participants will receive increasing doses of dobutamine infusion, and the effects on cardiac output and filling pressures will be assessed simultaneously by echocardiography and right heart catheterization.

Read the detailed description

AIMS

  • To investigate the hemodynamic effects of increasing dosages of dobutamine infusion on cardiac output and filling pressures in patients with symptomatic ATTRwt, assessed simultaneously by right heart catheterization (RHC) and echocardiography.
  • To assess the safety of dobutamine infusion in ATTRwt patients.

HYPOTHESIS

  • Dobutamine infusion can increase myocardial contractility significantly in patients with symptomatic ATTRwt
  • Dobutamin infusion can cause a significant decrease in the left ventricular filling pressure, as expressed by the pulmonary artery wedge pressure (PAWP) and/or mean pulmonary artery pressure (mPAP)
  • Dobutamine is well-tolerated and safe to use in symptomatic ATTRwt patients.

MATERIALS AND METHODS

Study population Symptomatic participants with ATTRwt, age ≥ 65 years, who have reduced left ventricular ejection fraction (LVEF) and/or stroke volume index (SVI), without significant valvular diseases or severe coronary artery diseases.

Study design

Eligible patients will be assessed on the trial day (one day) as following:

Step1; Baseline assessment: Blood pressure, pulse and ECG will be obtained. All participants will also undergo a comprehensive resting transthoracic echocardiographic assessment according to current guidelines.

Step 2; Invasive right heart catheterization (RHC): The subjects will be instructed not to eat for 6 hours and not to drink for 2 hours before the procedure. RHC will be performed in the cardiac invasive laboratory using right internal jugular vein access. Rarely, right femoral vein access will be used, if the right internal jugular vein is difficult to canulate, as a result of anatomical anomalies or local skin or muscle deformities. A 7 Fr sheath will be inserted in the vein aseptic, and ultrasound guided in local anaesthesia. Subsequently, a pulmonary catheter (Swan-Ganz) will be advanced through the sheath guided by pressure waves and fluoroscopy, through the right atrium, the right ventricle, and ultimately in a stable position in the pulmonary artery (PA). The standard Swan-Ganz catheter is equipped with an inflatable balloon at the tip, which facilitates its placement into the PA through the flow of blood. The balloon, when inflated, causes the catheter to "wedge" in a small pulmonary blood vessel. While wedged, the catheter can provide an indirect measurement of the mean left atrium pressure. Central oxygenation of the blood (SvO2) will be assessed from blood taken from the pulmonary artery at rest and at peak dobutamine infusion according to the protocol.

The PA catheter location will be confirmed with fluoroscopy before leaving the laboratory and both the sheath and the catheter will be fixed to the skin.

RHC is performed using a standard 7 Fr triple lumen Swan-Ganz catheter (Edwards Lifesciences, Irvine, California, USA).

The following parameters will be measured by RHC:

  • PAWP
  • Mean right atrial pressure
  • Systolic and diastolic PA pressure
  • mPAP
  • CO All pressures at rest are measured at end-expiration as the average of five measurements. CO is measured using thermodilution method and indexed to body surface area as the Cardiac Index (CI). . At baseline and peak infusion, CO will be the average of 3-4 measurements with \<10% variance; at intermediate dobutamine levels, 1-2 measurements will be taken as time allows. SV is calculated as CO divided by heart rate.

Step 3; Dobutamine challenge:

Dobutamine infusion will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2 (See appendix 1 for more information about dosage, administration and mixing of dobutamine). Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped. At each dobutamine infusion level, a stabilization period of 3 min is planned before echocardiographic image acquisition and haemodynamic measurements are obtained. Echocardiographic analysis will be performed later, blinded from the clinical and invasive data in a random order, to minimize the risk of bias.

Step 4; Recovery period: The pulmonary catheter and sheath will be removed after a-five minute recovery period, right after obtaining the final images and invasive measurements. The participants will be observed for 2 hours after the end of the test and will be discharged if no complications arise.

The investigators expect the study will last for about 6-7 hours, including preparations, waiting time, the procedures themselves and the observation period.

03

Conditions studied

  • ATTR Amyloidosis Wild Type

Keywords

  • Cardiac amyloidosis
  • Inotropic
  • ATTR-CM
  • Transthyretin amyloid cardiomyopathy
  • Dobutamine
  • wild type ATTR
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ATTRwt, diagnosis confirmed by genetic testing, 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) scintigraphy and/or endomyocardial .
  2. Treated with loop diuretics.
  3. class II-IV.
  4. Age ≥ 65 years.
  5. (LVEF) \< 50 % and/or SVI assessed by echocardiography \< 35 ml/m2.
  6. Thorough oral and written to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Moderate to severe aortic stenosis (participants with aortic sclerosis will not be excluded).
  2. Other significant valvular diseases.
  3. Known severe coronary artery diseases: left main stem stenosis or 3-vessel disease, or recent acute myocardial infarction (\< 4 weeks).
  4. to the use of dobutamine: Known allergy to dobutamine or sulfite, phaeochromocytoma or ventricular tachycardia (VT).
  5. End stage renal disease ( of less than 15 mL/min/1,73 m2).
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    ATTRwt

    Dobutamine (Dobutrex®) infusion.

    Drug: Dobutrex

Interventions

  • DrugDobutamineStudies of DobutamineDobutamine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Dobutamine (Dobutrex®) infusion. will be performed with a stepwise dobutamine dosage increase every 5 minutes (2,3,5,10,20 ug/kg/min). Dobutamine dosage will only be increased to 40 ug/kg/min in participants with ongoing beta-blocker treatment to ensure an appropriate dobutamine response. As dobutamine and its metabolites are excreted renally, the dose will be reduced to max 10 ug/kg/min in participants with eGFR below 30 mL/min/1,73 m2. Echocardiography, blood pressure, heart rate, and invasive pressure and flow measurements will be obtained before the infusion starts, at each infusion stage, and during the recovery period after the infusion is stopped.

    Also known as: Dobutamine

06

What researchers measure

Primary outcomes

  1. Cardiac output (CO)

    Changes in cardiac output evaluated by the thermodynamic invasive method.

    Time frame: Evaluated at every dobutamine dose-level, and at the end of infusion.

Secondary outcomes

  1. Changes in SVI measured invasively

    Time frame: Evaluated at every dobutamine dose-level, and at the end of infusion.

  2. Changes in PAWP and mPAP

    Time frame: Evaluated at every dobutamine dose-level, and at the end of infusion.

  3. Changes in LVEF and LV-GLS

    Time frame: Evaluated at every dobutamine dose-level, and at the end of infusion.

  4. Correlation between echo- and invasive measured SVI, and CO.

    Time frame: Evaluated at every dobutamine dose-level, and at the end of infusion.

  5. Rate of complications (i.e. Systolic blood pressure drop < 90 mmHg, arrhythmias)/symptomatic side effects.

    Time frame: Evaluated at every dobutamine dose-level, at the end of infusion, and during the 2 hours recovery period.

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2024 (actual). Primary completion is estimated for Jul 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2024
First posted
Mar 19, 2024
StartActual
Apr 8, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Sep 2027
Last update
Jun 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06318260
Lead sponsor
Steen Hvitfeldt Poulsen
Responsible party
Steen Hvitfeldt Poulsen (Professor, DMSc., Aarhus University Hospital Skejby) — Sponsor-investigator
First posted
Mar 19, 2024
Start date
Apr 8, 2024
Primary completion
Jul 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
Jun 1, 2026

Study contacts

Ali Hussein Jaber Mejren, MD
Contact
alimej@clin.au.dk
0045 91 65 18 48
Steen Hvitfeldt Poulsen, MD,PhD,DMSci
Contact
steepoul@rm.dk

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dobutamine

Start the discussion